You searched for "VEGF"

164 results found

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

The natural history of treatment naïve choroidal neovascularisation (CNV) in geographic atrophy

The aim of this retrospective study is to assess the characteristics and natural history of quiescent CNV in geographic atrophy (GA) utilising multi-modal imaging. Case notes were reviewed of patients diagnosed with geographic atrophy between January 2010 and December 2016...

Strategies for managing neovascular AMD and DMO in routine clinical care

Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Safety and efficacy of a nurse-led intravitreal injection service using an Precivia® injection assist device

Nurse-led intravitreal injections have become of great importance for busy eye units. In this article, the authors present safety data from five years of a nurse-led service with the use of the Precivia® intravitreal injection assist device. Intravitreal injections of...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Endophthalmitis after intravitreal injections in France

In this nationwide, retrospective, multicentre case series, the authors looked at the incidence and characteristics of endophthalmitis after intravitreal injections of anti-VEGFs and steroids, given for a variety of posterior segment conditions (macular oedema secondary to diabetes or retinal vein...

Intravitreal ranibizumab for the treatment of myopic CNV

The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...

The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD

Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...

Management of proliferative diabetic retinopathy

Diabetic retinopathy is a major cause of blindness in the working-age population. Due to the worsening global epidemic of diabetes, the incidence of morbidity caused by the disease is set to increase [1]. The prevalence of diabetes in the UK...

An uncommon late postoperative complication of combined cataract surgery and intravitreal triamcinolone injection

Case report A 64-year-old female with diabetic maculopathy (DMO) underwent phacoemulsification with intraocular lens (IOL) implantation in her right eye combined with intravitreal triamcinolone (IVTA). Diabetes control was poor with HbA1c (IFCC) of 119mmol/mol and blood sugar level of 27mmol/L....

Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?

This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...